论文部分内容阅读
目的 探讨c-erbB2 、nm2 3-H1和p5 3三种基因在宫颈癌中表达及其关系。方法 应用免疫组化法检测 4 0例宫颈癌组织及 10例宫颈不典型增生 ,2 0例宫颈炎组织标本中nm2 3-H1、c -erbB2 、p5 3蛋白表达 ,采用统计学 χ2 检验方法 ,分析这三种蛋白表达与临床病理及预后关系。结果 (1)宫颈癌nm2 3-H1蛋白表达率为 4 1.14 % ,宫颈炎组织表达为 5 .0 0 % ,不典型增生组织未见阳性表达 ,差异有显著性 (P <0 .0 1) ;表达与病理分类有关 ,腺癌表达为 83.33%高于鳞癌 32 .35 % ,差异有显著性(P <0 .0 5 ) ;(2 )c -erbB2 表达率为 37.5 0 % ,宫颈炎及不典型增生组织未见阳性表达 ,腺癌表达 6 6 .6 7% ,高于鳞癌 32 .35 % ,但无显著差异 (P >0 .0 5 ) ,鳞癌过表达与复发有关 ;(3)p5 3蛋白表达率为 2 4 .14 % ,宫颈炎组织未见阳性表达 ,1例重度不典型增生表达阳性 ,表达与宫颈癌病理分级相关。 2、三种基因蛋白表达的比较 :nm2 3-H1与c -erbB2 、p5 3与nm2 3-H1之间表达差异无显著性 (P >0 .0 5 ) ,p5 3与c -erbB2 之间表达差异有显著性 ,(P <0 .0 5 )。 3、c -erbB2 阳性 /p5 3阳性患者复发与c -erbB2 阴性+p5 3阴性患者复发组对照 ,差异有显著性。结论 nm2 3-H1表达在宫颈腺癌早期呈高表达 ,可能为机体抑制肿瘤?
Objective To investigate the expression of c-erbB2, nm2 3-H1 and p5 3 in cervical cancer and their relationship. Methods The expressions of nm23-H1, c-erbB2 and p5 3 in 40 cases of cervical cancer and 10 cases of cervical atypical hyperplasia and 20 cases of cervicitis were detected by immunohistochemistry. The statistical χ2 test was used to detect the expression of nm23- The relationship between these three proteins and clinical pathology and prognosis was analyzed. Results (1) The expression of nm23-H1 protein in cervical cancer was 4.14%, cervicitis was 5.0%, no expression was found in atypical hyperplasia (P <0.01) ; The expression was related to the pathological classification. The expression of adenocarcinoma in adenocarcinoma was 83.33% higher than that in squamous cell carcinoma (32.35%) (P <0.05). (2) The expression rate of c-erbB2 was 37.5% And atypical hyperplasia tissues showed no positive expression, the expression of adenocarcinoma was 66.76%, which was higher than that of squamous cell carcinoma (32.35%), but no significant difference (P> 0.05). The overexpression of squamous cell carcinoma was related to relapse. (3) The expression rate of p5 3 protein was 24.14%, no positive expression in cervicitis tissues, positive expression in one case of severe atypical hyperplasia, and the expression of p5 3 protein were correlated with the pathological grade of cervical cancer. There was no significant difference in the expressions of nm23-H1 and c-erbB2 between p5 3 and nm23-H1 (P> 0.05), between p5 3 and c-erbB2 The difference was significant (P <0.05). 3, c-erbB2 positive / p5 3-positive patients with recurrent c-erbB2-negative + p5 3 patients with negative control group, the difference was significant. Conclusion The expression of nm23-H1 is overexpressed early in cervical adenocarcinoma, which may be due to the inhibition of tumor in the body.